Cue Biopharma (CUE) Competitors

$25.33 -4.14 (-14.05%)

Closing price 04:00 PM Eastern

Extended Trading

$25.62 +0.29 (+1.14%)

As of 07:39 PM Eastern

CUE vs. AGMB, EPRX, LRMR, AUTL, and ENTA

Should you buy Cue Biopharma stock or one of its competitors? MarketBeat compares Cue Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cue Biopharma include AgomAb Therapeutics (AGMB), Eupraxia Pharmaceuticals (EPRX), Larimar Therapeutics (LRMR), Autolus Therapeutics (AUTL), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry.

How does Cue Biopharma compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Cue Biopharma (NASDAQ:CUE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

35.0% of Cue Biopharma shares are owned by institutional investors. 1.8% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AgomAb Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -96.85%. AgomAb Therapeutics' return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Cue Biopharma	-96.85%	-165.19%	-77.77%

AgomAb Therapeutics has higher earnings, but lower revenue than Cue Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Cue Biopharma	$27.47M	3.63	-$26.60M	-$9.61	N/A

In the previous week, Cue Biopharma had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 5 mentions for Cue Biopharma and 4 mentions for AgomAb Therapeutics. Cue Biopharma's average media sentiment score of 0.84 beat AgomAb Therapeutics' score of 0.30 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 189.86%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AgomAb Therapeutics beats Cue Biopharma on 6 of the 11 factors compared between the two stocks.

How does Cue Biopharma compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Eupraxia Pharmaceuticals presently has a consensus price target of $15.00, indicating a potential upside of 109.50%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -96.85%. Eupraxia Pharmaceuticals' return on equity of -87.56% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Cue Biopharma	-96.85%	-165.19%	-77.77%

Cue Biopharma has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Cue Biopharma	$27.47M	3.63	-$26.60M	-$9.61	N/A

Eupraxia Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 7 mentions for Eupraxia Pharmaceuticals and 5 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.84 beat Eupraxia Pharmaceuticals' score of 0.41 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Eupraxia Pharmaceuticals beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Larimar Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 1.8% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -96.85%. Larimar Therapeutics' return on equity of -137.70% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.70%	-101.43%
Cue Biopharma	-96.85%	-165.19%	-77.77%

Cue Biopharma has higher revenue and earnings than Larimar Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.21	N/A
Cue Biopharma	$27.47M	3.63	-$26.60M	-$9.61	N/A

In the previous week, Cue Biopharma had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for Cue Biopharma and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.89 beat Cue Biopharma's score of 0.84 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cue Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 324.16%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Larimar Therapeutics beats Cue Biopharma on 11 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Autolus Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 1.8% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cue Biopharma has a net margin of -96.85% compared to Autolus Therapeutics' net margin of -381.40%. Autolus Therapeutics' return on equity of -99.05% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-381.40%	-99.05%	-42.31%
Cue Biopharma	-96.85%	-165.19%	-77.77%

Cue Biopharma has lower revenue, but higher earnings than Autolus Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.61	-$287.53M	-$1.08	N/A
Cue Biopharma	$27.47M	3.63	-$26.60M	-$9.61	N/A

In the previous week, Autolus Therapeutics had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 8 mentions for Autolus Therapeutics and 5 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.84 beat Autolus Therapeutics' score of 0.45 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 450.31%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Autolus Therapeutics beats Cue Biopharma on 13 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to Enanta Pharmaceuticals?

Cue Biopharma (NASDAQ:CUE) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 6 mentions for Enanta Pharmaceuticals and 5 mentions for Cue Biopharma. Enanta Pharmaceuticals' average media sentiment score of 0.98 beat Cue Biopharma's score of 0.84 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Positive
Enanta Pharmaceuticals	Positive

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 1.8% of Cue Biopharma shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cue Biopharma has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.63	-$26.60M	-$9.61	N/A
Enanta Pharmaceuticals	$65.32M	6.14	-$81.89M	-$2.59	N/A

Cue Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 46.89%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Enanta Pharmaceuticals has a net margin of -89.56% compared to Cue Biopharma's net margin of -96.85%. Enanta Pharmaceuticals' return on equity of -68.72% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-96.85%	-165.19%	-77.77%
Enanta Pharmaceuticals	-89.56%	-68.72%	-20.41%

Summary

Enanta Pharmaceuticals beats Cue Biopharma on 13 of the 16 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$116.22M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-2.64	18.47	20.90	25.62
Price / Sales	3.63	295.31	549.01	77.56
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	2.51	6.93	9.93	6.96
Net Income	-$26.60M	$24.11M	$3.55B	$333.52M
7 Day Performance	-29.11%	0.08%	-0.33%	0.45%
1 Month Performance	-93.57%	0.84%	1.34%	4.06%
1 Year Performance	-96.22%	78.10%	41.10%	36.24%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	0.8982 of 5 stars	$25.33 -14.0%	N/A	-95.7%	$116.22M	$27.47M	N/A	60	Earnings Report Analyst Upgrade Short Interest Decrease
AGMB AgomAb Therapeutics	N/A	$11.97 -1.1%	$32.00 +167.4%	N/A	$434.30M	N/A	N/A	62	News Coverage Short Interest Increase
EPRX Eupraxia Pharmaceuticals	2.31 of 5 stars	$7.16 -3.6%	$15.00 +109.6%	+95.1%	$433.89M	N/A	N/A	29	Earnings Report Gap Up
LRMR Larimar Therapeutics	3.8859 of 5 stars	$4.16 -1.5%	$16.50 +297.1%	+118.1%	$431.62M	N/A	N/A	30	News Coverage Positive News Earnings Report
AUTL Autolus Therapeutics	3.3834 of 5 stars	$1.62 +2.9%	$8.50 +426.3%	+34.6%	$429.82M	$75.39M	N/A	330	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. AGMB, EPRX, LRMR, AUTL, and ENTA

How does Cue Biopharma compare to AgomAb Therapeutics?

Summary

How does Cue Biopharma compare to Eupraxia Pharmaceuticals?

Summary

How does Cue Biopharma compare to Larimar Therapeutics?

Summary

How does Cue Biopharma compare to Autolus Therapeutics?

Summary

How does Cue Biopharma compare to Enanta Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. AGMB, EPRX, LRMR, AUTL, and ENTA

How does Cue Biopharma compare to AgomAb Therapeutics?

Do insiders and institutionals have more ownership in AGMB or CUE?

Is AGMB or CUE more profitable?

Which has stronger earnings and valuation, AGMB or CUE?

Does the media prefer AGMB or CUE?

Do analysts rate AGMB or CUE?

Summary

How does Cue Biopharma compare to Eupraxia Pharmaceuticals?

Do analysts rate EPRX or CUE?

Is EPRX or CUE more profitable?

Do insiders and institutionals have more ownership in EPRX or CUE?

Which has stronger earnings and valuation, EPRX or CUE?

Which has more volatility and risk, EPRX or CUE?

Does the media refer more to EPRX or CUE?

Summary

How does Cue Biopharma compare to Larimar Therapeutics?

Which has more risk and volatility, LRMR or CUE?

Do institutionals & insiders hold more shares of LRMR or CUE?

Is LRMR or CUE more profitable?

Which has preferable earnings and valuation, LRMR or CUE?

Does the media refer more to LRMR or CUE?

Do analysts prefer LRMR or CUE?

Summary

How does Cue Biopharma compare to Autolus Therapeutics?

Which has more risk and volatility, AUTL or CUE?

Do institutionals & insiders hold more shares of AUTL or CUE?

Is AUTL or CUE more profitable?

Which has preferable earnings and valuation, AUTL or CUE?

Does the media refer more to AUTL or CUE?

Do analysts prefer AUTL or CUE?

Summary

How does Cue Biopharma compare to Enanta Pharmaceuticals?

Does the media prefer CUE or ENTA?

Do institutionals & insiders have more ownership in CUE or ENTA?

Which has higher valuation & earnings, CUE or ENTA?

Which has more volatility and risk, CUE or ENTA?

Do analysts recommend CUE or ENTA?

Is CUE or ENTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools